D. Frost

发表

Synthesis and biological evaluation of 4-[(3-methyl-3H-imidazol-4-yl)-(2-phenylethynyl-benzyloxy)-methyl]-benzonitrile as novel farnesyltransferase inhibitor.

Haiying Zhang, N. Lin, H. Sham, 2003, Bioorganic & medicinal chemistry letters.

Synthesis and biological evaluation of 4-[3-biphenyl-2-yl-1-hydroxy-1-(3-methyl-3H-imidazol-4-yl)-prop-2-ynyl]-1-yl-benzonitrile as novel farnesyltransferase inhibitor.

Haiying Zhang, N. Lin, H. Sham, 2003, Bioorganic & medicinal chemistry letters.

The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo.

Eric F. Johnson, X. Liu, V. Giranda, 2008, Anticancer research.

Potentiation of Temozolomide Cytotoxicity by Poly(ADP)Ribose Polymerase Inhibitor ABT-888 Requires a Conversion of Single-Stranded DNA Damages to Double-Stranded DNA Breaks

Eric F. Johnson, X. Liu, V. Giranda, 2008, Molecular Cancer Research.

ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors

P. Ellis, X. Liu, V. Giranda, 2009, Clinical Cancer Research.

An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.

P. Ellis, X. Liu, V. Giranda, 2008, Analytical biochemistry.

A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo.

Wang Shen, Mary K Joseph, Saul H Rosenberg, 2006, Cancer research.

The RTK inhibitor, ABT-869 alone or in combination with various cytotoxic therapies demonstrate significant tumor growth inhibition in orthotopic hepatocellular carcinoma, renal cell carcinoma and prostate xenografts

S. Davidsen, J. O'Connor, Baole Wang, 2007 .

AntitumorActivity of Orally Bioavailable Farnesyltransferase Inhibitor , ABT-100 , Is Mediated byAntiproliferative , Proapoptotic , and Antiangiogenic Effects in XenograftModels

S. Rosenberg, H. Sham, J. O'Connor, 2005 .

Antitumor Activity of Orally Bioavailable Farnesyltransferase Inhibitor, ABT-100, Is Mediated by Antiproliferative, Proapoptotic, and Antiangiogenic Effects in Xenograft Models

Haiying Zhang, N. Lin, H. Sham, 2005, Clinical Cancer Research.

ABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculature

G. Gordon, S. Rosenberg, G. Fox, 2009, Anti-cancer drugs.

Biological activity of A-289099: an orally active tubulin-binding indolyloxazoline derivative.

S. Ng, S. Rosenberg, S. L. Gwaltney, 2003, Molecular cancer therapeutics.

A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors.

S. Ng, J. Pietenpol, S. Rosenberg, 2001, Cancer research.

A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studies

V. Stoll, T. Holzman, S. Muchmore, 2005, Anti-cancer drugs.

Novel sulfonate derivatives: potent antimitotic agents.

S. Ng, P. Kovar, S. L. Gwaltney, 2001, Bioorganic & medicinal chemistry letters.

Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor.

Eric F. Johnson, X. Liu, V. Giranda, 2010, Journal of Medicinal Chemistry.

ABT-888 , an OrallyActive Poly ( ADP-Ribose ) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in PreclinicalTumorModels

Eric F. Johnson, T. DeWeese, X. Liu, 2007 .

Synthesis and biological evaluation of 2-indolyloxazolines as a new class of tubulin polymerization inhibitors. Discovery of A-289099 as an orally active antitumor agent.

S. Ng, P. Kovar, S. Rosenberg, 2002, Bioorganic & medicinal chemistry letters.

Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation.

S. Rosenberg, R. B. Credo, H. Sham, 2002, Journal of medicinal chemistry.

New antimitotic agents with activity in multi-drug-resistant cell lines and in vivo efficacy in murine tumor models.

S. Rosenberg, S. L. Gwaltney, R. B. Credo, 2001, Journal of medicinal chemistry.

ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models

Eric F. Johnson, T. DeWeese, X. Liu, 2007, Clinical Cancer Research.

Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer.

Eric F. Johnson, X. Liu, V. Giranda, 2008, Bioorganic & medicinal chemistry.

Design, synthesis, and activity of 4-quinolone and pyridone compounds as nonthiol-containing farnesyltransferase inhibitors.

V. Stoll, S. Muchmore, S. Rosenberg, 2004, Bioorganic & medicinal chemistry letters.

Synthesis and SAR of novel, potent and orally bioavailable benzimidazole inhibitors of poly(ADP-ribose) polymerase (PARP) with a quaternary methylene-amino substituent.

Eric F. Johnson, X. Liu, V. Giranda, 2008, Bioorganic & medicinal chemistry letters.

Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer.

Eric F. Johnson, X. Liu, V. Giranda, 2009, Journal of medicinal chemistry.

Benzimidazolones and indoles as non-thiol farnesyltransferase inhibitors based on tipifarnib scaffold: synthesis and activity.

V. Stoll, S. Rosenberg, H. Sham, 2005, Bioorganic & medicinal chemistry letters.

Design, synthesis, and activity of achiral analogs of 2-quinolones and indoles as non-thiol farnesyltransferase inhibitors.

V. Stoll, S. Rosenberg, N. Lin, 2005, Bioorganic & medicinal chemistry letters.

Discovery, SAR, synthesis, pharmacokinetic and biochemical characterization of A-192411: a novel fungicidal lipopeptide-(I).

L. Hasvold, H. Ding, Y. Hui, 2003, Bioorganic & medicinal chemistry letters.

Aryl tetrahydropyridine inhibitors of farnesyltransferase: bioavailable analogues with improved cellular potency.

V. Stoll, S. Muchmore, S. Ng, 2003, Bioorganic & medicinal chemistry letters.

Synthesis and activity of 1-aryl-1'-imidazolyl methyl ethers as non-thiol farnesyltransferase inhibitors.

V. Stoll, S. Rosenberg, Gary T. Wang, 2004, Bioorganic & medicinal chemistry letters.

A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation.

M. Bergo, S. Young, C. Coffinier, 2006, The Journal of clinical investigation.

A Protein Farnesyltransferase Inhibitor Ameliorates Disease in a Mouse Model of Progeria

Stephen G Young, S. Young, C. Coffinier, 2006, Science.

Novel sulfonate analogues of combretastatin A-4: potent antimitotic agents.

S. Ng, P. Kovar, S. L. Gwaltney, 2001, Bioorganic & medicinal chemistry letters.

Noninvasive molecular imaging of apoptosis in vivo using a modified firefly luciferase substrate, Z-DEVD-aminoluciferin

D. Klaubert, S. Ackler, J. Bouska, 2010, Cell Death and Differentiation.

Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2.

Scott A. Erickson, J. Maris, Chang H. Park, 2003, Cancer research.

Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML

G. Borthakur, M. Motwani, R. Gandour-Edwards, 2022, In Vivo.

Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models

C. Tse, S. Fesik, S. Rosenberg, 2008, Clinical Cancer Research.

Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agents.

P. Ellis, Eric F. Johnson, N. Soni, 2009, Journal of medicinal chemistry.

Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth

T. Jorgensen, H. Tian, I. Joseph, 2007, Cancer Chemotherapy and Pharmacology.

ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo

C. Tse, S. Fesik, S. Chemburkar, 2008, Molecular Cancer Therapeutics.

The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo

Saul H. Rosenberg, Stephen W. Fesik, C. Tse, 2010, Cancer Chemotherapy and Pharmacology.

Novel and selective imidazole-containing biphenyl inhibitors of protein farnesyltransferase.

S. Muchmore, H. Sham, M. Curtin, 2003, Bioorganic & medicinal chemistry letters.

ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo

S. Fesik, S. Chemburkar, S. Rosenberg, 2008, Molecular Cancer Therapeutics.

Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer.

Eric F. Johnson, X. Liu, V. Giranda, 2009, Journal of medicinal chemistry.